Stachydrine Protects Against Pressure Overload-Induced Cardiac Hypertrophy by Suppressing Autophagy

Abstract

Background: Autophagy is required for the maintenance of cardiomyocyte homeostasis. However, excessive autophagy plays a maladaptive role in pressure overload-induced heart failure. To identify mechanisms by which Stachydrine inhibits pressure overload-induced cardiac hypertrophy, we determined inhibitory activities against activation of NADPH oxidase, reactive oxygen species(ROS) production and excessive activation of autophagy. Methods: Stachydrine was administered intragastrically to Wistar rats after Transverse aortic constriction(TAC) and H9c2 cells were treated with Stachydrine after Angiotension II stimulation. The activation of NADPH oxidase2 required the membrane translocation of p47phox and p67phox. Cell membrane fraction was isolated by ultracentrifuge in sucrose. The expression of p67phox, p47phox, gp91phox subunit in the cell membrane were determined by western blot. The combination of p67phox and gp91 phox subunit was detected by immunofluorescence staining. The expression of phosphorylated p47phox subunit was determined by western blot. The intracellular ROS were measured with DCF-DA fluoresence. The autophagic flux was measured by recording the fluorescence emission of the fusion protein mRFP-GFP-LC3 by dynamic live-cell imaging. Reuslts: We report here that stachydrine, a major constituent of Leonurus heterophyllus Sweet, inhibited AngII-induced excessive autophagy within H9c2 cells. Stachydrine blocked the over phosphorylation of the p47phox subunit, decreased the translocation of p47phox and p67phox to the membrane, inhibited the activity of NOX2, and reduced the generation of ROS. We also demonstrated that stachydrine ameliorated TAC-induced cardiac hypertrophy, dysfunction and excessive autophagy in vivo. Conclusions: Our study highlights the importance of regulating NOX2 when autophagy is obviously activated. By inhibiting NOX2, Stachydrine inhibits ROS production, thus exerting a remarkable activity of inhibiting hypertrophy, which could have considerable effect on clinical practice.

Atorvastatin Attenuates Myocardial Hypertrophy in Spontaneously Hypertensive Rats via the C/EBPβ/PGC-1α/UCP3 Pathway

“…Besides thermogenesis and the regulation of ATP synthesis, there are two other primary hypotheses regarding the physiological roles of UCP3: the regulation of fatty acid oxidation and the reduction of the mitochondrial generation of ROS [28]. And previous study showed that myocardial hypertrophy was accompanied by increasing of ROS production [29, 30]. The downregulation of UCP3 has previously been reported in hypertrophic myocardium and heart failure [31, 32].…”

Synergistic therapeutic effects of Duzhong Jiangya Tablets and amlodipine besylate combination in spontaneously hypertensive rats using 1H‐NMR‐ and MS‐based metabolomics

“…The structures are shown in Figure 1. Some studies have shown that these ingredients influence the cardiovascular system (Cao et al, 2017;Gao, Chen, Liang, Xie, & Chen, 2015;Huang et al, 2017;Olaleye, Crown, Akinmoladun, & Akindahunsi, 2014).…”

Stachydrine prevents LPS‐induced bone loss by inhibiting osteoclastogenesis via NF‐κB and Akt signalling

“…Over several years, our group has screened natural compounds for treating osteoclast‐related diseases . Stachydrine (STA), a bioactive constituent extracted from a medicinal herb Leonurus heterophyllus Sweet, has extensive pharmacological properties, including antioxidant, anti‐inflammatory, anticancer and cardioprotective properties . Recent studies have reported that STA inhibits NF‐κB and MAPK pathways in different cell types .…”

“…[13][14][15][16] Stachydrine (STA), a bioactive constituent extracted from a medicinal herb Leonurus heterophyllus Sweet, has extensive pharmacological properties, including antioxidant, anti-inflammatory, anticancer and cardioprotective properties. [17][18][19][20] Recent studies have reported that STA inhibits NF-κB and MAPK pathways in different cell types. [20][21][22] As the NF-κB and MAPK pathways are crucial for osteoclastogenesis and because STA exerts inhibitory effects on these pathways, we hypothesized that STA may represent a novel candidate for treating osteoclast-related diseases by inducing the targeted suppression of osteoclastogenesis.…”